B. Camitta

发表

Relationship of CRLF2 expression and outcome in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): A report from the Children's Oncology Group.

M. Loh, C. Mullighan, C. Willman, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

C. Pui, R. Gelber, E. Korn, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986–1994

J. Shuster, J. Pullen, S. Murphy, 2000, Leukemia.

Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome

C. Pui, J. Shuster, N. Heerema, 2004, Leukemia.

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

M. Tallman, O. Ringdén, R. Martino, 2004, Bone Marrow Transplantation.

A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: A Pediatric Oncology Group study (now The Children's Oncology Group)

J. Shuster, B. Bostrom, B. Camitta, 2004, Pediatric blood & cancer.

E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study.

M. Cleary, S. Hunger, A. Carroll, 1998, Blood.

In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype

M. D. Boer, R. Pieters, A. Veerman, 2004, Leukemia.

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).

M. Loh, J. Shuster, N. Heerema, 2007, Blood.

Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study

M. Borowitz, J. Rubnitz, B. Camitta, 1998, Leukemia.

Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.

Kevin K Dobbin, Edward J Bedrick, Walker Wharton, 2010, Blood.

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.

J. Downing, K. Dobbin, C. Mullighan, 2010, Blood.

Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.

C. Pui, W. Kamps, A. Baruchel, 2000, The New England journal of medicine.

Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report

M. Amylon, J. Kurtzberg, M. Link, 2000, Leukemia.

Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study.

J. Shuster, M. DeBaun, B. Pollock, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.

N. Winick, B. Camitta, R. Nitschke, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia

M. Loh, M. Relling, Cheng Cheng, 2011, Nature Genetics.

Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Michael N. Edmonson, M. Loh, J. Downing, 2011, Blood.

Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.

J. Shuster, B. Camitta, D. Mahoney, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study.

J. Shuster, C. Civin, B. Camitta, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission.

J. Shuster, B. Pollock, A. Rimm, 1994, The New England journal of medicine.

Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study.

A. Look, J. Shuster, Y. Ravindranath, 1998, Leukemia & lymphoma.

New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a pediatric oncology group report of 343 cases.

J. Shuster, M. Amylon, M. Link, 2000, Blood.

Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031

N. Heerema, S. Hunger, M. Borowitz, 2014, Leukemia.

Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia.

M. Horowitz, N. Flomenberg, L. Baxter‐Lowe, 1994, Blood.

Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies

F. Behm, S. Raimondi, M. Relling, 2000, Leukemia.

Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial

C. Pui, S. Jeha, C-H Pui, 2001, Leukemia.

Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.

M. Relling, C. Pui, G. Reaman, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term results of large prospective trials in childhood acute lymphoblastic leukemia

C. Pui, S. Sallan, M. Schrappe, 2000, Leukemia.

Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study

M. Amylon, J. Kurtzberg, M. Link, 1999, Leukemia.

Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States.

A. Zander, M. Horowitz, J. Liesveld, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial

C. Pui, H. Kantarjian, S. Jeha, 2005, Leukemia.

Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.

J. Sierra, J. Dipersio, S. Tarima, 2010, Blood.

Identification of leukemic cells in the cerebrospinal fluid from children with acute lymphoblastic leukemia: advances and dilemmas.

B. Camitta, S. Lauer, P. Kirchner, 1989, The American journal of pediatric hematology/oncology.

Minimal residual disease detection in childhood precursor–B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study

J J Shuster, J. Shuster, C. Willman, 2003, Leukemia.

Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821

S. Raimondi, A. Carroll, Y. Ravindranath, 2000, Leukemia.

Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children.

M. Amylon, Y. Ravindranath, J. Pullen, 1997, Blood.

Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.

M. Loh, J. Gastier-Foster, C. Mullighan, 2012, Blood.

Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.

M. Loh, M. Relling, Cheng Cheng, 2013, Journal of the National Cancer Institute.

syndrome and acute myeloid leukemia Allogeneic transplantation for therapy-related myelodysplastic

J. Sierra, J. Dipersio, S. Tarima, 2011 .

Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study.

Alan M. Miller, P. D. Dal Cin, J. Sierra, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

PharmGKB Update: II. CYP3A5, Cytochrome P450, Family 3, Subfamily A, Polypeptide 5

E. Cook, M. Boguski, F. Behm, 2004, Pharmacological Reviews.

Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia.

J. Klein, M. Horowitz, R. Gale, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study.

J. Krischer, B. Camitta, J. Boyett, 1991, Journal of neurosurgery.

Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements

C. Pui, N. Heerema, A. Baruchel, 2003, Leukemia.

Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival.

James, Rimm, K., 1989, Blood.

Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs.

B. Monia, N. Dean, M. Diccianni, 2002, Leukemia research.

Home care for dying children: a nursing model.

B. Camitta, M. Lauer, B. Camitta, 1980, The Journal of pediatrics.

High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study.

J. Shuster, H. Friedman, D. Wall, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia.

H. Deeg, E. Guinan, B. George, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children’s Oncology Group Study AALL0031

N. Heerema, M. Devidas, A. Carroll, 2014, Leukemia.

Intensive Alternating Drug Pairs After Remission Induction for Treatment of Infants With Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Pilot Study

J. Shuster, A. Carroll, J. Pullen, 1998, Journal of pediatric hematology/oncology.

Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation.

J. Downing, F. Behm, S. Raimondi, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.